LivaNova (LIVN) came into focus after management raised full year 2026 revenue guidance to a range of 9% to 10% growth, alongside third quarter results that showed higher sales and improved profitability compared with last year.
LivaNova’s upgraded outlook landed after a strong price run, with the share price at $91.32 and a 30 day share price return of 17.71% adding to a year to date gain of 50.59%. The 1 year total shareholder return of 64.96% and 3 year total shareholder return of 95.25% point to momentum that has been building rather than fading.
Scan for other medical technology stocks riding similar earnings and guidance momentum by reviewing the hand picked list of solid balance sheet and fundamentals (24 results) alongside LivaNova.
LivaNova now appears to be a healthier operation, supported by a sharp rerating in the share price. The real work for investors is to determine what that combination is actually worth today.
LivaNova is trading at $91.32 against a narrative fair value of $105.09, which the analyst consensus Narrative on Simply Wall St links to detailed assumptions on growth, profitability and discount rates that use an 8.09% hurdle.
The main thing that has to go right is that LivaNova executes on elevated capital investment in capacity, IT and digital platforms so that cardiopulmonary upgrades, neuromodulation launches and connected care tools translate into sustained profitable growth and improved free cash flow conversion by 2028.
See why 5 investors see LivaNova as 13% undervalued.
Result: Fair Value of $105.09 (UNDERVALUED)
Still, the narrative around LivaNova can crack if heavy 2026 capital spending fails to lift cash generation, or if epilepsy reimbursement support reverses and compresses procedure volumes.
Find out about the key risks to this LivaNova narrative.
Mixed sentiment around LivaNova is clear, with both risk and reward signals on the table. Consider acting promptly by reviewing the details and deciding where you stand after weighing the 3 key rewards and 2 important warning signs.
Once you have a view on LivaNova, do not stop there. Use the same momentum to look for other opportunities before the market moves on without you.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com